DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety and Efficacy Study of Add On Aliskiren in Patients With Heart Failure and Renal Impairment

Information source: University Medical Center Groningen
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Heart Failure; Kidney Failure

Intervention: Aliskiren (Drug); Placebo (Drug)

Phase: Phase 2

Status: Terminated

Sponsored by: University Medical Center Groningen

Summary

The main purpose of this study is to examine the effect of add-on therapy with the direct renin inhibitor Aliskiren in comparison to placebo on renal blood flow in patients with heart failure and reduced renal function.

- Primary outcome measure: change in renal blood flow at 6 months

- Secondary outcome measures: changes in renal function, N-terminal pro Brain natriuretic

peptide, left ventricular function, blood pressure and neurohormones

Clinical Details

Official title: A Double-blind, Placebo-controlled, Randomized Trial Investigating the Safety and Efficacy of Additive Renin Inhibition With Aliskiren on Renal Blood Flow and Neurohormonal Activation in Patients With Chronic Heart Failure and Renal Dysfunction

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome: Change in renal blood flow as assessed by 131I-Hippuran clearance

Secondary outcome:

change in glomerular filtration rate (GFR) as assessed by 125I-Iothalamate

Change in systolic and diastolic blood pressure

change in N-terminal pro brain natriuretic peptide levels (NT-proBNP)

Change in left ventricular ejection fraction

change in NYHA class, change in filtration fraction, change in albumin excretion, change in tubular function parameters, change in neurohormonal activation

Detailed description: This study is a randomized, double-blind, placebo controlled, parallel group comparison trial, enrolling 100 patients (67 vs. 33) with stable CHF. Patients will be randomized to Aliskiren 300 mg once daily or corresponding Placebo for a period of 6 months. Efficacy measures will be performed at baseline and at the end of the study. Primary efficacy outcome is change in renal blood flow as measured by 131I-Hippuran clearance. Secondary outcome include change in renal function, neurohormones, left ventricular function and blood pressure. Safety assessments include renal function, changes in electrolytes, and blood pressure. Patients will be uptitrated to maximum tolerated doses of Aliskiren, and safety visits are planned 1 week after initiation and on a 2 month interval afterwards. A total of 8 visits are planned during the entire study period.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- NYHA II-IV Heart Failure

- Left ventricular ejection fraction < 45%

- Stable heart failure medication

- eGFR by sMDRD formula between 30 and 60 mL/min/1. 73m2

Exclusion Criteria:

- Known hypersensitivity to study drug or ACEi

- Concomitant treatment with both ARB and Aldosterone Receptor Antagonist

- Symptomatic Hypotension

- Acute Heart Failure

- History of stroke, acute coronary syndrome, PCI or angioplasty within past 3 months

- Serum potassium > 5. 2 mmol/L

- Right heart failure due to severe pulmonary disease

- Other protocol-defined inclusion/exclusion criteria may apply

Locations and Contacts

University Medical Center Groningen, Groningen, Netherlands
Additional Information

Related publications:

McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J; Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008 May;1(1):17-24. doi: 10.1161/CIRCHEARTFAILURE.107.740704.

Starting date: April 2009
Last updated: May 16, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017